Clinical trials
Phase 2 Alzheimer Disease trials in Canada
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 5 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 7 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 6 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 47 |
| Terminated | 17 |
| Recruiting | 8 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| GlaxoSmithKline | 6 |
| Eli Lilly and Company | 5 |
| Sunnybrook Health Sciences Centre | 5 |
| Boehringer Ingelheim | 4 |
| OPKO Health, Inc. | 4 |
| Genentech, Inc. | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Pfizer | 3 |
| AbbVie | 2 |
| AbbVie (prior sponsor, Abbott) | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alzheimer Disease | 75 |
| Dementia | 22 |
| Cognitive Dysfunction | 11 |
| Brain Diseases | 7 |
| Central Nervous System Diseases | 6 |
| Neurodegenerative Diseases | 6 |
| Nervous System Diseases | 5 |
| Tauopathies | 5 |
| Mental Disorders | 4 |
| Neurocognitive Disorders | 4 |
Trials
Showing 1 to 25 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.